|
EP0919544B1
(en)
*
|
1992-04-02 |
2003-05-14 |
Smithkline Beecham Corporation |
Compounds useful for treating allergic and inflammatory diseases
|
|
EP1466598A3
(en)
*
|
1993-06-18 |
2007-06-27 |
Smithkline Beecham Corporation |
PDE-IV inhibitors
|
|
EP0722322B1
(en)
*
|
1993-10-01 |
2001-11-14 |
Smithkline Beecham Corporation |
Compounds, compositions and treatment of allergies and inflammation therewith
|
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
|
EP0799184A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
DIMERS 4.4- (DISUBSTITUTED) CYCLOHEXAN-1-OL AND RELATED COMPOUNDS
|
|
ZA9510826B
(en)
*
|
1994-12-23 |
1996-06-20 |
Smithkline Beecham Corp |
3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
|
|
JPH10511390A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
1,4,4−(三置換)シクロヘクス−1−エンダイマーおよび関連化合物
|
|
JPH10511391A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
3,3−(二置換)シクロヘキサン−1−オール二量体および関連化合物
|
|
EP0799204A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
MONOMERS OF 1,3,3- (TRISUBSTITUE) CYCLOHEXANE AND RELATED COMPOUNDS
|
|
ATE306260T1
(de)
*
|
1994-12-23 |
2005-10-15 |
Smithkline Beecham Corp |
Monomere der 4,4-(disubstituierten)cyclohexan-1- ole und verwandte verbindungen
|
|
AU698028B2
(en)
*
|
1995-05-18 |
1998-10-22 |
Altana Pharma Ag |
Phenyldihydrobenzofurans
|
|
DE59610031D1
(de)
*
|
1995-05-18 |
2003-02-06 |
Altana Pharma Ag |
Cyclohexyldihydrobenzofurane
|
|
AR004471A1
(es)
*
|
1995-05-31 |
1998-12-16 |
Smithkline Beecham Corp |
Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
|
US6288261B1
(en)
|
1998-12-18 |
2001-09-11 |
Abbott Laboratories |
Inhibitors of matrix metalloproteinases
|
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
|
US20020077276A1
(en)
*
|
1999-04-27 |
2002-06-20 |
Fredeking Terry M. |
Compositions and methods for treating hemorrhagic virus infections and other disorders
|
|
UY26268A1
(es)
*
|
1999-08-06 |
2001-01-31 |
Smithkline Beecham Corp |
Procedimiento para preparar acidos a traves de alfa-cloroep xi- esteres ley 17164 art 127
|
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
|
CA2715683A1
(en)
|
1999-08-21 |
2001-03-01 |
Nycomed Gmbh |
Synergistic combination
|
|
US6572794B1
(en)
|
2000-07-24 |
2003-06-03 |
Essilor International Compagnie Generale D'optique |
Method of manufacturing a photochromic molded article
|
|
FR2816950B1
(fr)
|
2000-11-17 |
2003-02-14 |
Essilor Int |
Procede d'obtention d'un latex photochromique
|
|
FR2819258B1
(fr)
|
2001-01-11 |
2003-04-11 |
Essilor Int |
Procede d'obtention d'un latex photochromique stabilise, latex obtenu et application a l'optique ophtalmique
|
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
PL218992B1
(pl)
|
2002-07-19 |
2015-02-27 |
Abbott Biotech Ltd |
Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
EA200501548A1
(ru)
|
2003-04-01 |
2006-02-24 |
Апплайд Резеч Системз Арс Холдинг Н.В. |
Ингибиторы фосфодиэстераз при бесплодии
|
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20070078120A1
(en)
*
|
2003-10-21 |
2007-04-05 |
Hitoshi Ban |
Novel piperidine derivative
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
艾伯維生物技術有限責任公司 |
用於治療TNFα相關失調症之多重可變劑量療法
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
US7910708B2
(en)
|
2005-10-21 |
2011-03-22 |
Novartis Ag |
Anti-IL13 human antibodies
|
|
PT1948235E
(pt)
|
2005-11-01 |
2013-11-26 |
Abbvie Biotechnology Ltd |
Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EP2738179A1
(en)
|
2006-04-05 |
2014-06-04 |
AbbVie Biotechnology Ltd |
Antibody purification
|
|
EP2708242A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of ankylosing spondylitis
|
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
ATE549337T1
(de)
|
2006-04-21 |
2012-03-15 |
Novartis Ag |
Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
|
|
TWI498137B
(zh)
|
2006-06-30 |
2015-09-01 |
Abbvie Biotechnology Ltd |
自動注射裝置
|
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
|
|
KR20090075714A
(ko)
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
소염제로서의 헤테로시클릭 화합물
|
|
RS51644B
(sr)
|
2007-01-10 |
2011-10-31 |
Irm Llc. |
Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
|
|
RU2009141592A
(ru)
*
|
2007-04-11 |
2011-05-20 |
Алькон Рисерч, Лтд. (Us) |
ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
|
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
|
KR20100005730A
(ko)
|
2007-05-07 |
2010-01-15 |
노파르티스 아게 |
유기 화합물
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
|
EA017919B1
(ru)
|
2007-12-10 |
2013-04-30 |
Новартис Аг |
Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
|
|
EP2231642B1
(en)
|
2008-01-11 |
2013-10-23 |
Novartis AG |
Pyrimidines as kinase inhibitors
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
MX2011011541A
(es)
|
2009-04-29 |
2012-02-28 |
Abbott Biotech Ltd |
Dispositivo de inyeccion automatico.
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
RU2012117141A
(ru)
*
|
2009-10-01 |
2013-11-10 |
Алькон Рисерч, Лтд. |
Композиции олопатадина и способы их применения
|
|
EP2813227A1
(en)
|
2009-10-22 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
EP2513144A1
(en)
|
2009-12-16 |
2012-10-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
WO2011097301A2
(en)
|
2010-02-02 |
2011-08-11 |
Abbott Biotechnology Ltd. |
METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
KR101850687B1
(ko)
|
2010-04-21 |
2018-04-20 |
애브비 바이오테크놀로지 리미티드 |
치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
|
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
|
CA2801917C
(en)
|
2010-06-03 |
2017-04-25 |
Abbvie Biotechnology Ltd |
Uses and compositions for treatment of hidradenitis suppurativa (hs)
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
RU2602039C2
(ru)
|
2011-01-24 |
2016-11-10 |
Эббви Байотекнолоджи Лтд. |
Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
|
AU2012220572A1
(en)
|
2011-02-25 |
2013-08-29 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
CA3100941C
(en)
|
2011-03-01 |
2024-03-05 |
Synergy Pharmaceuticals Inc. |
Process of preparing guanylate cyclase c agonists
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
ES2882807T3
(es)
|
2011-09-16 |
2021-12-02 |
Novartis Ag |
Heterociclil carboxamidas N-sustituidas
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
US20130209543A1
(en)
|
2011-11-23 |
2013-08-15 |
Intellikine Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
CN110507654A
(zh)
|
2012-04-03 |
2019-11-29 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
EP3718557A3
(en)
|
2013-02-25 |
2020-10-21 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
EA201592263A1
(ru)
|
2013-06-05 |
2016-05-31 |
Синерджи Фармасьютикалз, Инк. |
Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
|
|
KR20160042039A
(ko)
|
2013-08-09 |
2016-04-18 |
알데릭스, 인코포레이티드 |
인산염 수송을 억제하기 위한 화합물 및 방법
|
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
EP3134397A1
(en)
|
2014-04-24 |
2017-03-01 |
Novartis AG |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
PL3134395T3
(pl)
|
2014-04-24 |
2018-07-31 |
Novartis Ag |
Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
|
|
US10112926B2
(en)
|
2014-04-24 |
2018-10-30 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
EP3145951A1
(en)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
KR20170036037A
(ko)
|
2014-07-31 |
2017-03-31 |
노파르티스 아게 |
조합 요법
|
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
|
WO2020048828A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Pharma Aktiengesellschaft |
5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
|
|
WO2020048827A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
|
|
WO2020237096A1
(en)
|
2019-05-21 |
2020-11-26 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
|
EP3980121A1
(en)
|
2019-06-10 |
2022-04-13 |
Novartis AG |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
|
PH12022550468A1
(en)
|
2019-08-28 |
2023-03-06 |
Novartis Ag |
Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
|
|
US20260086394A1
(en)
|
2022-04-26 |
2026-03-26 |
Essilor International |
Photochromic optical article having a mirror coating
|